Patents Assigned to Memgen, LLC
  • Armed oncolytic viruses
    Patent number: 11298420
    Abstract: Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 12, 2022
    Assignee: MEMGEN, LLC
    Inventor: Mark J. Cantwell
  • METHODS OF CD40 AND TOLL LIKE RECEPTOR IMMUNE ACTIVATION
    Publication number: 20200353044
    Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of a TLR agonist and a chimeric CD154 polypeptide. Also provided herein are methods of enhanced immune function.
    Type: Application
    Filed: April 11, 2018
    Publication date: November 12, 2020
    Applicant: MEMGEN, LLC
    Inventors: Willem OVERWIJK, Manisha SINGH, Patrick HWU, Mark CANTWELL
  • METHODS OF CD40 ACTIVATION AND IMMUNE CHECKPOINT BLOCKADE
    Publication number: 20200165339
    Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 28, 2020
    Applicants: Board of Regents, The University of Texas System, Memgen, LLC
    Inventors: Willem W. OVERWIJK, Manisha SINGH, Patrick HWU, Mark CANTWELL
  • METHODS FOR TREATMENT OF CANCER
    Publication number: 20180244750
    Abstract: Provided herein are methods of sensitizing cancer cells to treatment with inhibitors of the PD-1 pathway. Such methods comprise treatment of subject with a checkpoint inhibitor refractory cancer with an expression vector encoding a chimeric CD154.
    Type: Application
    Filed: November 2, 2016
    Publication date: August 30, 2018
    Applicant: Memgen, LLC
    Inventor: Mark J. Cantwell
  • ARMED ONCOLYTIC VIRUSES
    Publication number: 20180169241
    Abstract: Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 21, 2018
    Applicant: Memgen, LLC
    Inventor: Mark J. Cantwell
  • ARMED REPLICATION-COMPETENT ONCOLYTIC ADENOVIRUSES
    Publication number: 20180169271
    Abstract: Disclosed are replication-competent oncolytic adenoviruses, comprising chimeric human/mouse CD40 ligands. The oncolytic adenoviruses may be replication competent. The chimeric human/mouse CD40 ligand may be MEM40. Also disclosed are methods comprising administering a replication competent oncolytic adenovirus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from a cancer.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 21, 2018
    Applicants: Memgen, LLC, DNAtrix
    Inventors: Mark J. Cantwell, Winnie M. Chan, Brett Ewald, Joan M. Robbins